Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — H1 2023 Earnings Presentation
18 slides from Zealand Pharma A/s's earnings presentation, Aug 17, 2023
Slide 1: H1 2023 Interim Report
H1 2023 Interim Report Zealand Pharma August 17, 2023
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: H1 2023 characterized by strong progress in obesity portfolio and regulatory submissions
H1 2023 characterized by strong progress in obesity portfolio and regulatory submissions for dasiglucagon NON-EXHAUSTIVE Survodutide Announced advancement Submitted NDA to US FDA for dual GLU/GLP-1 to Phase 3 following dasiglucagon in congenital receptor agonist positive Phase 2 results hyperinsulin
Slide 4: In 2023 we have three key strategic objectives focused on maximizing value
In 2023 we have three key strategic objectives focused on maximizing the value potential of our pipeline 1 Progress rare disease assets 2 3 Engage in strategic Advance obesity portfolio toward regulatory submission partnership discussions ✓ Dasiglucagon for congenital Survodutide1 (GCGR/GLP-1R) Rare
Slide 5: Our R&D pipeline addresses unmet medical needs across several therapeutic areas
Our R&D pipeline addresses unmet medical needs across several therapeutic areas Product Candidate* Preclinical Phase 1 Phase 2 Phase 3 Registration , diseases Dasiglucagon: S.C. Continuous Infusion Congenital Hyperinsulinism Rare Glepaglutide (GLP-2 Analog) Short Bowel Syndrome Survodutide (GCGR/GLP
Slide 6: Increased focus on potential for differentiation by addressing treatment gap of 15-25% weight loss
Increased focus on potential for differentiation by addressing treatment gap of 15-25% weight loss 5% Intensive lifestyle therapy First-generation Anti-Obesity 10% Medications (AOMs) Total body weight loss 15% Differentiated anti-obesity treatments Treatment gap and for the majority of people 20% hi
Slide 7: Success of future anti-obesity medications will be determined by differentiation on multiple fronts
Success of future anti-obesity medications will be determined by differentiation on multiple fronts GLP-1 backbone GLP-1 mono Examples of differentiation factors • Effect on co-morbidities to obesity, such as CVD, NASH, GLP-1/GIP T2D, CKD, OA GLP-1/Glu* • Improved tolerability by addressing GI side
Slide 8: Zealand Pharma has a rich obesity pipeline of differentiated product candidates
Zealand Pharma has a rich obesity pipeline of differentiated product candidates Developed with GLP-1 receptor Initially developed as monotherapy agonist foundation but with potential for combination GLP-1 • Increase insulin sensitivity • Delay gastric emptying • Decrease appetite + Glucagon + GLP-2
Slide 9: Survodutide treatment dose-dependently reduced bodyweight up to 18.7% over 46 weeks
Survodutide treatment dose-dependently reduced bodyweight up to 18.7% over 46 weeks • At Week 46, significant weight reductions were seen with all tested survodutide doses versus placebo (p<0.01) • Up to 40% of participants receiving survodutide achieved bodyweight reductions of ≥20% after 46 weeks
Slide 10: Long-acting amylin analog ZP8396 is a non-incretin for obesity treatment
Long-acting amylin analog ZP8396 is a non-incretin for the potential treatment of overweight and obesity • Doses of 0.6 and 1.2 mg ZP8396 administered once-weekly for six weeks led to 5.3% and 5.1% mean weight loss in healthy lean and overweight people1 • This compares to 2.6%, 3.6% and 4.2% mean we
Slide 11: We have submitted the NDA to the US FDA for dasiglucagon in congenital hyperinsulinism
We have submitted the NDA to the US FDA for dasiglucagon in congenital hyperinsulinism Aim to enter into a partnership agreement in H2 2023 • CHI is a rare disease that affects babies and children • Dasiglucagon administered as a continuous subcutaneous infusion via a wearable pump system Notes: Inv
Slide 12: H1 2023 Profit & Loss
H1 2023 Profit & Loss DKK million H1 2023 H1 2022 P&L reflecting Zealand’s ambition to be leading peptide drug discovery and development company while commercializing products through partnerships Revenue 24.0 36.3 • Revenue of DKK 24 million in H1 2023 is driven by the agreement with Novo Gross mar
Slide 13: Strong cash position allows for investments in R&D
Strong cash position allows for investments in R&D DKK million Cash position of DKK 2,042 million as of June 30, 20231 2,500 2,042 2,042 -526 2,000 350 350 1,500 1,500 1,178 -372 1,000 1,365 -88 500 328 0 Cash position Cash Other cash Capital raise Repayment Cash 2020 2021 2022 30-Jun-23 year-end fl
Slide 14: 2023 financial guidance confirmed
2023 financial guidance confirmed DKK million 2023 2022 Guidance Actual Revenue anticipated from existing and new license and No guidance 104 partnership agreements due to uncertain size and timing Net operating expenses1 800 - 900 941 Notes 1. Net operating expenses consist of R&D, S&M, G&A and oth
Slide 15: Multiple events and catalysts during the next 12 months across several therapeutic areas
Multiple events and catalysts during the next 12 months across several therapeutic areas DIRECTIONAL H2 2023 H1 2024 Survodutide Survodutide Initiation of Ph3 trials Topline results from Ph2 trial in NASH Dapiglutide ZP8396 (amylin) Initiation of Ph1b dose titration trial Topline results from MAD Pa
Slide 16: On track to deliver on our strategic priorities in 2023
On track to deliver on our strategic priorities in 2023 Progress rare Engage in disease Advance strategic assets toward obesity partnership regulatory portfolio discussions submissions 16
Slide 17: Obesity R&D Event in Q4 2023
Obesity R&D Event in Q4 2023 Presenters to include Management and Lead investigators In-person event at Zealand Pharma’s headquarters outside Copenhagen (plus webcast) 17
Slide 18: Q&A session
Q&A session• H1 2023 presentation August 17, 2023 18